Cureus Protective Adaptive Immunity Against Severe Acute Respiratory Syndrome Coronaviruses 2 (SARS-CoV-2) and Implications for Vaccines

[tetano]

Cureus


. 2020 Jun 1;12(6):e8399.
doi: 10.7759/cureus.8399.
Protective Adaptive Immunity Against Severe Acute Respiratory Syndrome Coronaviruses 2 (SARS-CoV-2) and Implications for Vaccines


Christopher Manners ¹ , Erick Larios Bautista ¹ , Hannah Sidoti ¹ , Osvaldo J Lopez ¹



Affiliations

• PMID: 32499988
• PMCID: PMC7268578
• DOI: 10.7759/cureus.8399

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging human coronavirus responsible for coronavirus disease 2019 (COVID-19), a predominantly respiratory disease that has become a global pandemic. Millions of people worldwide are suffering from COVID-19, and hundreds of thousands of those infected have died. Nevertheless, many more people who have been infected with SARS-CoV-2 are asymptomatic or suffer a mild disease characterized by dry cough and mild fever. This new pandemic poses a threat to public health on a global scale, and an intervention to prevent continued spread of SARS-CoV-2 virus is of the utmost importance. To assess preventive and therapeutic strategies, it is imperative to understand the pathogenesis and immune response against SARS-CoV-2. In this review, we concentrate on the protective adaptive immune response elicited by this novel coronavirus as well as requirements for a successful vaccine inducing optimal protection.

Keywords: covid-19; neutralizing antibodies; sars-cov-2; t-cell immunity; vaccines.